...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules
【24h】

Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules

机译：大量肝细胞癌结节患者的预后因素

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background:The prognostic factors and treatment strategies for hepatocellular carcinoma (HCC) patients with a large number of tumor nodules have not been fully elucidated. Clinical factors influencing prognosis were investigated in HCC patients with 30 or more tumor nodules.Methods:Forty-six HCC patients with 30 or more tumor nodules participated in this study. None of them had vascular invasion and extrahepatic metastasis. Kaplan-Meier curve and Cox proportional hazard model were used for analysis.Results:The median survival time of our patients was no more than 15 months, suggesting that patients with 30 or more tumor nodules may be regarded as a progressive subgroup showing poorer prognosis. In multivariate analysis, presence of between 30 and 59 tumor nodules (P = 0.002), male gender (P = 0.002), lower total bilirubin (total bilirubin 1.0 mg/dL) (P = 0.011), transarterial chemoembolization (TACE) as an initial therapy (P = 0.027) and higher prothrombin time (P = 0.049) were significant independent factors for better overall survival. Among 39 patients who underwent TACE as an initial therapy, patients who received sorafenib therapy during follow-up showed better overall survival than those who did not (P = 0.026). Efficacy of sorafenib appeared to be more evident in patients who needed repeated transarterial treatment.Conclusions:In HCC patients with 30 or more tumor nodules, TACE as an initial therapy may be correlated with better prognosis. Sorafenib administration after the prior transarterial treatment may improve antitumor efficacy.Copyright 2020, Abe et al.
机译：背景：肝细胞癌（HCC）具有大量肿瘤结节患者的预后因素和治疗策略尚未完全阐明。在HCC患者中研究了影响预后的临床因素，患有30次或更多次肿瘤结节的患者。方法：本研究参加了46例HCC患者，具有30名肿瘤结节。他们都没有血管侵袭和脱毛转移。 Kaplan-Meier曲线和Cox比例危险模型用于分析。结果：我们患者的中位生存时间不超过15个月，表明肿瘤结节30或更多的患者可被视为表现出较差的亚组，显示出较差的亚组。在多变量分析中，存在30至59个肿瘤结节（p = 0.002），雄性性别（P = 0.002），低总胆红素（总胆红素<1.0mg / dl）（p = 0.011），易转化栓塞（TACE）为初始治疗（P = 0.027）和更高的凝血酶原时间（p = 0.049）是较好整体存活的重要因素。在39名接受TACE作为初步治疗的患者中，在随访期间接受Sorafenib治疗的患者表现出比没有（P = 0.026）的总生存率更好在需要重复常规治疗的患者中，索拉非尼的疗效似乎更加明显。结论：在HCC患者中，肿瘤结节30或以上的肿瘤结节，作为初始治疗的TACE可能与更好的预后相关。索拉芬蛋白在先前的培养治疗后给药可以改善抗肿瘤效率。柔毛2020，Abe等人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号